Track Forte Biosciences's operating income ($-90M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
As of the most recent data (June 2026), FBRX shows a operating income of $-90M. That compares with $-44M in the prior-year period — down 106.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, FBRX's operating income is now $-90M (was $-44M) — a 106.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Forte Biosciences is outperforming or lagging.
Tracking FBRX's operating income over time shows whether Forte Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-90M That compares with $-44M in the prior-year period — down 106.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has Forte Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-90M) with ownership activity and broader fundamentals.
Forte Biosciences's operating income is $-90M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.